@article{Shankar-Hari_M-2025_221344,
title = {A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19},
author = {Shankar-Hari, M. and Francois, B. and Remy, K. and Gutierrez, C. and Pastores, S. and Daix, T. and Jeannet, R. and Blood, J. and Walton, A. and Salomao, R. and Auzinger, G. and Striker, D. and Martin, R. and Anand, N. and Bosanquet, J. and Blood, T. and Brakenridge, S. and Moldawer, L. and Vachharajani, V. and Yee, C. and Dal-Pizzol, F. and Morre, M. and Berbille, F. and van den Brink, M. and Hotchkiss, R.},
month = {mar},
year = {2025},
abstract = {BACKGROUND: Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients' ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function.},
volume = {10},
issue = {6},
journal = {JCI Insight},
publisher = {American Society for Clinical Investigation},
url = { https://doi.org/10.1172/jci.insight.189150},
}
